Jefferies Healthcare

Temperature Check

An annual pulse check on global healthcare—capturing sentiment, priorities and expectations across investors, corporates and industry leaders.

Foreword

I am pleased to share the ninth edition of the Jefferies Healthcare Temperature Check, our annual report capturing the sentiment, priorities and expectations shaping the global healthcare industry. Each year, over 600 senior healthcare professionals, consultants and investors participate, offering a timely view of how leaders are thinking about capital allocation priorities, technological and scientific innovation, and strategic decision-making.

The past year has shown evidence of healthcare’s resilience despite uncertainty. Dogged inflation, rising interest rates, questions about drug pricing and geopolitical volatility have made it harder and more costly to operate. And yet, there continue to be positive developments across the industry, underlining healthcare’s status as a defensive asset class.

Strategic dealmaking continues to gather pace, as demonstrated by our work with EQT on its take-private of Qiagen, and also with CVC and GBL on the take-private of Recordati – both deals worth over $10bn in value. Biopharma, biotech and corporate M&A remain active as companies search for new sources of growth. Notably, healthcare equities are still widely expected to finish 2027 higher than they are now, and this year’s survey indicated lots of positive momentum more broadly, with innovation from GLP-1s and AI viewed as the sector’s key drivers.

At Jefferies, we too are optimistic about the implications of AI-led transformation for drug discovery and manufacturing, and are also excited by the investment opportunities in spec pharma and CDMOs. A key example of this in Spec Pharma is our work with SUN PHARMA out of India in May, who acquired Organon in the largest healthcare transaction in Indian history, worth over $10bn in value. Another example is our recent work with Cinven on the acquisition of Theramex from Carlye and PAI for a rumoured circa EUR 2.6bn. And finally, work we did with MannKind on their acquisition of scPharmaceuticals as they build an exciting, larger innovative spec pharma company in the US. Similarly, in CDMOs, we’re also seeing a bottoming out and renewal of activity from what has been a relatively quiet 12 to 18 months up to now, which in large part is being driven by a surge in biotech funding.

Looking towards 2027, there is good reason for cautious confidence. Healthcare businesses continue to see resilient demand while scientific progress is driving the industry on, even against a stormy risk backdrop. At Jefferies, we look forward to supporting companies and investors in pursuing exciting opportunities, and to continuing productive conversations at our Jefferies Global Healthcare Conference in London.

The Market Outlook

The outlook for healthcare equity markets remains positive. 55% of respondents expect the MSCI World Health Care Index to finish 2027 higher, while 46% expect the FTSE 100 to do so. These findings are broadly consistent with the 2025 survey, when 58% and 50% of respondents, respectively, expected the MSCI World Health Care Index and the FTSE 100 to finish 2026 higher. Both views have proved correct so far in 2026.

Respondents also remain constructive on healthcare allocations. 42% expect to increase their exposure in 2027, compared with 46% in the previous survey. A further 35% expect to maintain their exposure, while only 4% anticipate reducing it. Together, these findings suggest continued support for healthcare allocations, albeit without a material increase in conviction from last year.

However, this positive outlook is tempered by broader uncertainty. Geopolitical uncertainty remains the leading perceived risk, cited by 38% of respondents, while 72% are very or somewhat concerned about its impact on their businesses or investments. This points to a market in which confidence in healthcare’s prospects is balanced against a less predictable external environment.

0%

Expect the FTSE 100 to be higher at the end of 2027

Corporate M&A
Expected to Dominate

0%

of respondents expect healthcare M&A activity to increase in 2027

Corporate-led M&A is expected to dominate transaction activity, selected by 58% of respondents, an 8-percentage point increase from the 2025 survey. This compares with only 12% selecting private equity-led M&A, suggesting that respondents expect strategic buyers to be better positioned to pursue transactions as financial sponsors continue to navigate a more challenging fundraising, financing and exit environment.

Expectations for equity financing also remain subdued. Only 9% of respondents expect equity financing, including IPOs, to dominate healthcare transaction activity in 2027, compared with 12% in 2025 and 20% in 2024. Together, the findings point to a selective transaction environment in which corporate balance sheets are expected to play a greater role, while sponsor-led activity and public market issuance remain more constrained. The capital markets environment was also identified as the third most significant risk facing the sector.

North America leads as China gains ground

0%

North America remains the leading perceived value opportunity for healthcare investment in 2027, selected by 73% of respondents, 26 percentage points ahead of China. It has ranked first in every survey conducted during the 2020s. Institutional investors expressed the strongest conviction, with 86% selecting the region as one of the greatest value opportunities for healthcare investment.

China has nevertheless continued to gain ground, moving ahead of Europe excluding the United Kingdom to become the second most widely selected value opportunity, chosen by 47% of respondents. China ranked between third and fourth in the 2018 to 2024 surveys before drawing level with Europe for the first time last year and moving independently into second place this year.

This shift coincides with growing international interest in Chinese healthcare innovation, including record levels of biopharma out-licensing activity as global pharmaceutical companies seek access to new drug candidates. China’s share of global commercial clinical trials has also increased from 10% to 30% over the past decade, while Europe’s share has declined from 18% to 9%.

Together, the findings suggest that North America retains the strongest combination of scale, innovation, and investment opportunity, while China is becoming increasingly important not only as an end market, but also as a source of scientific and commercial innovation.

Mid- and Small-Cap Pharma & Biotech Most Expected to Outperform

Mid- and Small-Cap Pharma & Biotech remains the publicly traded healthcare segment most widely expected to perform best over the next 12 months, selected by 46% of respondents. Large-Cap Pharma & Biotech ranked second at 19%.

However, the proportion selecting the segment declined by 7 percentage points from 53% in 2025. The change was particularly pronounced among institutional investors, with 36% selecting it compared with 53% in the previous survey. Each of the other listed segments received a higher share of selections than last year.

The results suggest that it remains the clearest area of expected public market outperformance, but with conviction becoming less concentrated as expectations improve across other listed healthcare segments.

0%

expect mid and small cap pharma and biotech to perform best in 2027

GLP-1s Expected to Maintain their Momentum

0%

Elsewhere in the survey, 62% strongly agreed that GLP-1s will continue to deliver sustained long-term growth. Anti-obesity medication was also the area of biopharma innovation most commonly expected to have the greatest impact in 2027.

The principal anticipated growth drivers are new drug-delivery methods, including oral formulations, selected by 61% of respondents; expansion into additional therapeutic areas, selected by 59%; and increased reimbursement and physician confidence, selected by 43%. These findings suggest that respondents see the next stage of growth being driven by broader formats, indications, and access, rather than simply greater adoption of existing products.

Challenges remain. Pricing pressure was ranked as the leading challenge by 40% of respondents, while 45% included adverse side effects among their three biggest challenges facing incumbents in the GLP-1 market. The results therefore point to continued confidence in the market’s expansion, but also to increasing competitive and commercial complexity as the category matures.

AI is Delivering Tangible Benefits

Health monitoring and predictive analytics are expected to benefit most over the next 1 to 3 years, selected by 71% of respondents, followed by administrative efficiency at 56% and genomics and personalised medicine at 42%. The prominence of monitoring, analytics and administrative efficiency suggests that respondents expect the most immediate benefits to emerge in areas where AI can improve decision-making and productivity, ahead of more complex clinical applications.

Expectations for bioconvergence are more long term, with 61% of respondents believing it has significant future potential but is unlikely to have a major impact over the next 12 months. The contrast with AI underlines that respondents distinguish between technologies already producing tangible benefits and those whose commercial impact may take longer to develop.

0%

agree AI is already having a tangible impact on Healthcare

Conclusion

The Jefferies Healthcare Temperature Check 2026 points to a constructive but increasingly selective outlook for healthcare in 2027. Respondents remain positive on equity markets, allocations and M&A, but geopolitical uncertainty and subdued capital markets expectations temper confidence.

The findings suggest that capital is likely to remain available, but more selectively deployed. Corporate buyers are expected to lead dealmaking, established markets continue to attract the strongest investment interest, and respondents remain focused on areas where scientific innovation can translate into tangible clinical and commercial outcomes.

Overall, respondents are not retreating from healthcare. Rather, they are becoming more discerning about where value will emerge. The ability to combine innovation with scale, access to capital and commercial execution is likely to be increasingly important in determining performance in 2027.

Video Interviews

Global Joint Head of Healthcare

EMEA Head of Biotechnology

0+

0+

IMPORTANT: You must read the following before reading, accessing or making any other use of this publication. In accessing this publication, you agree to be bound by the following terms and conditions. This document is being furnished for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to purchase any security or other financial instrument or product. It is not intended to form the basis of any investment decision. Jefferies International Limited and its affiliates (together “Jefferies”) makes no representation as to the accuracy or completeness of the information contained herein or any other information, whether written or oral, made available. Jefferies disclaims all and any liability whatsoever, whether arising in tort, contract or otherwise, for the contents of this publication. You acknowledge that Jefferies does not owe you or any other person or entity, any fiduciary or similar duty as a result of the publication of this report, and Jefferies is not providing any advice, including with respect to legal, tax, accounting, investment or regulatory matters, in any jurisdiction.